Abstract: Human lymphocyte-associated cell surface protein LAM-1, which includes domains homologous with binding domains of animal lectins, growth factors, and C3/C4 binding proteins, and the cDNA encoding LAM-1, are described. Antagonists to LAM-1 are used in a method of treating a human patient suffering from a lymphocyte-mobilizing condition which involves administering a therapeutic amount of the antagonist in a non-toxic pharmaceutical carrier substance. Additionally, antibodies that bind human LAM-1 and inhibit cellular adhesion, migration or infiltration into tissues are described.
Abstract: The present invention describes monoclonal antibodies which are useful for the specific detection of diffuse gastric carcinoma. Further embodiments describe therapeutic and diagnostic means for the detection and for the therapy of diffuse gastric carcinomas.
Type:
Grant
Filed:
July 23, 1997
Date of Patent:
September 10, 2002
Assignee:
GSF Forschungszentrum fur Umwelt und Gesundheit GmbH
Inventors:
Heinz Höfler, Karl-Friedrich Becker, Elisabeth Kremmer, Manfred Eulitz, Christoph Schuhmacher
Abstract: Peanuts are a common cause of food hypersensitivity reactions. The sera of 10 patients who had atopic dermatitis and a positive double-blind placebo-controlled food challenge to peanut were used to investigate the major allergens of peanut. Crude Florunner extracts were fractionated by anion-exchange chromatography using a step gradient (limit buffer, 0.05M BisTris/1.5M NaCl). One hundred microliters of each 2.0 ml fraction was dot-blotted onto nitrocellulose paper and IgE-binding activity assessed using the serum pool to select allergen-containing fractions. A protein peak (OD 280) which eluted at 10% NaCl and demonstrated intense IgE-binding was further analyzed by two-dimensional SDS-PAGE/immunoblot analysis. The majority of this fraction is a protein which has a molecular weight of 17 kD and a pI of 5.2. Sequencing data from the N-terminus revealed the following initial 9 amino acids: (*)-Q-Q-(*)-E-L-Q-D-L.
Abstract: Isolated cDNA molecules which encode the tumor rejection antigen precursor MAGE-10, the protein itself, antibodies to it, and uses of these are part of the invention.
Type:
Grant
Filed:
August 18, 2000
Date of Patent:
May 14, 2002
Assignee:
Ludwig Institute for Cancer Research
Inventors:
Donata Rimoldi, Victor Jongeneel, Pierre Coulie, Jean-Charles Cerrottini, Stefan Carrel, Daryl Reed
Abstract: Carcinoma associated antigen (SK1) and monoclonal antibodies and methods for detecting and ameliorating malignant disease. The monoclonal antibodies are specifically reactive with epitopes present on SK1.
Type:
Grant
Filed:
June 10, 1997
Date of Patent:
March 12, 2002
Assignee:
Viventia Biotech Inc.
Inventors:
Mark C. Glassy, Helena R. Chang, Keiji Koda
Abstract: The present invention provides methods for producing antibodies against a variety of antigens, including mammalian antigens with highly conserved epitopes. In addition, the present invention provides improved methods and compositions for the cloning and manipulation of immunoglobulin genes as well as antibodies derived therefrom.
Type:
Grant
Filed:
August 6, 1997
Date of Patent:
November 13, 2001
Assignee:
Arch Development Corporation
Inventors:
Nancy M. Michael, Mary Ann V Accavitti, Craig B. Thompson
Abstract: Monoclonal antibodies with specificity for membrane-associated antigens and methods of using them in detection of tumor-associated antigens arc described.
Type:
Grant
Filed:
February 1, 1995
Date of Patent:
September 25, 2001
Assignee:
Dade Behring Marburg GmbH
Inventors:
Klaus Bosslet, Roland Kurrle, Hans Harald Sedlacek, Ernst-Jurgen Kanzy, Takako Katoh, Hans Ulrich Schorlemmer, Gerhard Luben
Abstract: An anti-CEA monoclonal antibody, designated 806.077, of murine origin is useful for the diagnosis and therapy of cancer. The antibody complementarity determining regions have the following sequences: heavy chain CDR1 DNYMH, CDR2 WIDPENGDTE YAPKFRG, CDR3 LIYAGYLAMD Y; and light chain CDR1 SASSSVTYMH, CDR2 STSNLAS, CDR3 QQRSTYPLT. The antibody optionally is humanized and can be in the form of a conjugate with either an enzyme, such as carboxypeptidase, or a co-stimulatory molecule such as the extracellular domain of human B7.1.
Type:
Grant
Filed:
October 29, 1998
Date of Patent:
August 21, 2001
Assignee:
Zeneca Limited
Inventors:
Clive Graham Copley, Michael Derek Edge, Stephen Charles Emery
Abstract: The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.
Type:
Grant
Filed:
December 2, 1998
Date of Patent:
July 10, 2001
Assignee:
The Regents of the University of California
Abstract: This invention provides tumor metastasis-inhibiting monoclonal antibodies, mAb 41-2, mAb 50-6 and mAb 1A-5. The antigen recognized by mAb 50-6 and mAb 1A-5 has been identified as the PETA-3 antigen. The antigen recognized by mAb 41-2 has been identified as a novel tumor metastasis-associated antigen. Compositions and methods are provided that are useful for treating and diagnosing metastatic tumors.
Type:
Grant
Filed:
June 15, 1999
Date of Patent:
June 12, 2001
Assignee:
The Research Foundation of State University of New
York
Inventors:
Jacqueline E. Testa, James P. Quigley, Marco Seandel
Abstract: Monoclonal antibodies against dihydropyrimidine dehydrogenase are disclosed. Immunologic assays using the monoclonal antibodies are also disclosed.
Abstract: The present invention provides an anti-idiotypic antibody having specific reactivity with an idiotope common to more than one type of anti-HIV-1 antibody, and having no specific reactivity with non-HIV-1 antibodies. The present invention provides methods of diagnosis, monitoring and treatment of HIV-related diseases through the use of this antibody or related compounds.
Abstract: A monoclonal antibody which is specific to a polypeptide having a molecular weight of 18, 500±3,000 daltons on SDS-PAGE and a pI of 4.9±1.0 on chromatofocusing. The monoclonal antibody is obtainable from hybridomas and can be used for the purification and detection of the polypeptide. The polypeptide strongly induces the IFN-&ggr; production by immunocompetent cells with only a small amount, and does not cause serious side effects even when administered to human in a relatively-high dose.
Abstract: The invention relates to monoclonal antibodies (MAbs) and fragments thereof which bind to defined tumor-associated antigens, principally of small cell lung carcinoma (SCLC), of melanoma, of neuroblastoma and other tumors of neuroectodermal origin, to hybridoma cell lines for the preparation thereof, and to the antigens which can be defined and/or isolated with the aid of these antibodies or antibody fragments. The antibodies, antibody fragments and antigens can be used as diagnostic, aid, active substance or active substance carrier.
Type:
Grant
Filed:
June 16, 1999
Date of Patent:
March 19, 2002
Assignee:
Dade Behring Marburg GmbH
Inventors:
Klaus Bosslet, Bernhard Auerbach, Helmut Peters